Canada - English - Health Canada

boiron laboratoires - anacardium orientale - tablet - 1dh - anacardium orientale 1dh - homeopathic products

Canada - English - Health Canada

dolisos laboratoires s.a. - anacardium orientale - tablet - 1dh - anacardium orientale 1dh - homeopathic products

Canada - English - Health Canada

homeocan inc. - anacardium orientale - tablet - 1dh - anacardium orientale 1dh - homeopathic products

Canada - English - Health Canada

homeocan inc. - anacardium occidentale - tablet - 3dh - anacardium occidentale 3dh - homeopathic products

Canada - English - Health Canada

laboratoires holis inc. - anacardium orientale - tablet - 3x - anacardium orientale 3x - homeopathic products

United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - anacardium occidentale fruit (unii: 4a10jr4e7e) (anacardium occidentale fruit - unii:4a10jr4e7e) - dermatitis condition listed above or as directed by the physician.

United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - semecarpus anacardium juice (unii: y0f0bu8rdu) (semecarpus anacardium juice - unii:y0f0bu8rdu) - poison ivy, mental fatigue condition listed above or as directed by the physician.

United States - English - NLM (National Library of Medicine)

azurity pharmaceuticals, inc. (formerly arbor pharmaceuticals) - gabapentin enacarbil (unii: 75ocl1spbq) (gabapentin - unii:6cw7f3g59x) - gabapentin enacarbil 300 mg - horizant® is indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls) in adults. horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night. horizant is indicated for the management of postherpetic neuralgia (phn) in adults. none. risk summary there are no adequate data on the developmental risk associated with the use of horizant in pregnant women. in nonclinical studies in rats and rabbits, administration of gabapentin enacarbil was developmentally toxic when administered to pregnant animals at doses and gabapentin exposures greater than those used clinically [see data] . in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data when pregnant rats were administered gabapentin enacarbil (oral d

Australia - English - Department of Health (Therapeutic Goods Administration)

kl4 pty ltd - terminalia chebula, quantity: 100 mg (equivalent: terminalia chebula, qty 50 mg); moringa oleifera, quantity: 100 mg; glycyrrhiza glabra, quantity: 50 mg (equivalent: glycyrrhiza glabra, qty 50 mg); semecarpus anacardium, quantity: 50 mg; plumbago europaea, quantity: 50 mg; anacardium occidentale, quantity: 10 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica - traditionally used in ayurvedic medicine to kapha & vata roga/relieve kapaha & vata disturbance

Malta - English - Medicines Authority

adamed sp. z.o.o. pieńków 149, 05-152 czosnów, poland - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals